INmune Bio: Alzheimer’s Trial Results and Stock Shock

The recent news surrounding INmune Bio has sent ripples through the biotechnology investment world, causing the company's stock to plummet by over 50%. This dramatic drop wasn't due to a scandal or financial mismanagement, but rather the outcome of a clinical trial for their Alzheimer's disease drug, XPro.